BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38181298)

  • 1. Role of whole body MRI in paraneoplastic/autoimmune syndromes: An MRPET study to standardize protocols, pattern interpretation, and establish yield of MRI.
    Mangalore S; Vankayalapati S; Gupta AK
    Medicine (Baltimore); 2024 Jan; 103(1):e36413. PubMed ID: 38181298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-Body
    Sheikhbahaei S; Marcus CV; Fragomeni RS; Rowe SP; Javadi MS; Solnes LB
    J Nucl Med; 2017 Jul; 58(7):1031-1036. PubMed ID: 27980049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates.
    Basu S; Alavi A
    Mol Imaging Biol; 2008; 10(3):131-7. PubMed ID: 18297363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated whole-body PET/MR hybrid imaging: clinical experience.
    Quick HH; von Gall C; Zeilinger M; Wiesmüller M; Braun H; Ziegler S; Kuwert T; Uder M; Dörfler A; Kalender WA; Lell M
    Invest Radiol; 2013 May; 48(5):280-9. PubMed ID: 23442775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging Workup of Suspected Classical Paraneoplastic Neurological Syndromes: A Systematic Review and Retrospective Analysis of
    Sundermann B; Schröder JB; Warnecke T; Heindel W; Schäfers M; Weckesser M; Buerke B
    Acad Radiol; 2017 Oct; 24(10):1195-1202. PubMed ID: 28551401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
    Schmidt GP; Kramer H; Reiser MF; Glaser C
    Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-body nonenhanced PET/MR versus PET/CT in the staging and restaging of cancers: preliminary observations.
    Huellner MW; Appenzeller P; Kuhn FP; Husmann L; Pietsch CM; Burger IA; Porto M; Delso G; von Schulthess GK; Veit-Haibach P
    Radiology; 2014 Dec; 273(3):859-69. PubMed ID: 25102372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Harlos C; Metser U; Poon R; MacCrostie P; Mason W
    Curr Oncol; 2019 Aug; 26(4):e458-e465. PubMed ID: 31548813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG-PET/MRI in the diagnostic work-up of limbic encephalitis.
    Deuschl C; Rüber T; Ernst L; Fendler WP; Kirchner J; Mönninghoff C; Herrmann K; Quesada CM; Forsting M; Elger CE; Umutlu L
    PLoS One; 2020; 15(1):e0227906. PubMed ID: 31951636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging--pilot study.
    Schwenzer NF; Schraml C; Müller M; Brendle C; Sauter A; Spengler W; Pfannenberg AC; Claussen CD; Schmidt H
    Radiology; 2012 Aug; 264(2):551-8. PubMed ID: 22653189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of PET and MR datasets in integrated 18F-FDG PET/MRI: A comparison of different MR sequences for whole-body restaging of breast cancer patients.
    Grueneisen J; Sawicki LM; Wetter A; Kirchner J; Kinner S; Aktas B; Forsting M; Ruhlmann V; Umutlu L
    Eur J Radiol; 2017 Apr; 89():14-19. PubMed ID: 28267530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contrast-enhanced PET/MR imaging versus contrast-enhanced PET/CT in head and neck cancer: how much MR information is needed?
    Kuhn FP; Hüllner M; Mader CE; Kastrinidis N; Huber GF; von Schulthess GK; Kollias S; Veit-Haibach P
    J Nucl Med; 2014 Apr; 55(4):551-8. PubMed ID: 24491410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses.
    Drzezga A; Souvatzoglou M; Eiber M; Beer AJ; Fürst S; Martinez-Möller A; Nekolla SG; Ziegler S; Ganter C; Rummeny EJ; Schwaiger M
    J Nucl Med; 2012 Jun; 53(6):845-55. PubMed ID: 22534830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging.
    Yi CA; Shin KM; Lee KS; Kim BT; Kim H; Kwon OJ; Choi JY; Chung MJ
    Radiology; 2008 Aug; 248(2):632-42. PubMed ID: 18552311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT.
    Ohno Y; Koyama H; Onishi Y; Takenaka D; Nogami M; Yoshikawa T; Matsumoto S; Kotani Y; Sugimura K
    Radiology; 2008 Aug; 248(2):643-54. PubMed ID: 18539889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation.
    Umutlu L; Beyer T; Grueneisen JS; Rischpler C; Quick HH; Veit-Haibach P; Eiber M; Purz S; Antoch G; Gatidis S; Nikolaou K; Schaefer JF; Rausch I; Herrmann K; ;
    Nuklearmedizin; 2019 Mar; 58(2):68-76. PubMed ID: 30818412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma?
    Aryal A; Kumar VS; Shamim SA; Gamanagatti S; Khan SA
    Clin Orthop Relat Res; 2021 Aug; 479(8):1768-1779. PubMed ID: 33635285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.